stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) Return on equity
Repligen Corporation's return on equity over the twelve months to 30 September 2026 was −0.57%, down 3.0 percentage points from fiscal 2025 (2.40%). Over the past ten years it has ranged from −1.30% (fiscal 2024) to 10.2% (fiscal 2022); the current reading is higher than 27% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 2.40% | 3.70 |
| FY2024 | −1.30% | (3.14) |
| FY2023 | 1.84% | (8.32) |
| FY2022 | 10.2% | 2.34 |
| FY2021 | 7.82% | 3.19 |
| FY2020 | 4.63% | 2.07 |
| FY2019 | 2.56% | (0.19) |
| FY2018 | 2.75% | (4.71) |
| FY2017 | 7.46% | (0.55) |
| FY2016 | 8.01% | 0.04 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ATR AptarGroup, Inc. compare | 9.86% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| AVTR Avantor, Inc. compare | 5.91% |
| SOLV Solventum Corporation compare | 3.19% |
| ALGN Align Technology, Inc. compare | 0.00% |
| RGEN Repligen Corporation | −0.57% |
| BLCO Bausch + Lomb Corporation compare | −1.71% |
| BAX Baxter International Inc. compare | −10.6% |
| TFX Teleflex Incorporated compare | −28.9% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement